SCHEMBL23218740

SCHEMBL23218740

CC(=O)COc1ccc(Br)c2occc12

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.42
MAOA P21397 6/20 0.41
MAOB P27338 6/20 0.41
SMN1; SMN2 Q16637 3/20 0.38
KDM4E B2RXH2 2/20 0.38
NPC1 O15118 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
RAB9A P51151 2/20 0.38
HSD17B10 Q99714 2/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
TP53 P04637 1/20 0.38
KCNA3 P22001 6/20 0.37
KCNA2 P16389 1/20 0.36
KCNA4 P22459 1/20 0.36
KCNA5 P22460 1/20 0.36
KCNA1 Q09470 1/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23218543 0.88 KMT2A (0.42) KMT2AMAOAMAOBSMN1; SMN2KDM4E
SCHEMBL23087443 0.80 KDM4E (0.40) SMN1; SMN2KDM4EALDH1A1HPGDRAB9A
SCHEMBL2120997 0.74 ALDH1A1 (0.42) KMT2ASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL7693059 0.72 KCNA3 (0.41) MAOAMAOBSMN1; SMN2KDM4EALDH1A1
SCHEMBL4334809 0.72 POLB (0.53) KMT2ASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL24901718 0.70 KCNA3 (0.34) KMT2ASMN1; SMN2ALDH1A1KCNA3
SCHEMBL28772658 0.68 HDAC1 (0.36) KCNH2
SCHEMBL26287513 0.68 CA1 (0.38) KMT2ASMN1; SMN2KDM4ENPC1ALDH1A1
SCHEMBL24901723 0.68
SCHEMBL29128176 0.67 GRM4 (0.58) KMT2ASMN1; SMN2KDM4ENPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB KMT2A 4445/4885MAOA 1416/4885MAOB 1035/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB KMT2A 4835/4885MAOA 795/4885MAOB 453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.